{
  "consolidation_metadata": {
    "timestamp": "20250905_122745",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_types": [
      "picos"
    ],
    "pico_metadata": {
      "timestamp": "2025-09-05T12:27:03.246413",
      "total_consolidated_picos": 13,
      "source_countries": [
        "DE",
        "DK",
        "EN",
        "FR",
        "NL",
        "PO",
        "PT",
        "SE"
      ],
      "source_types": [
        "clinical_guideline",
        "hta_submission"
      ],
      "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context"
    }
  },
  "consolidated_picos": [
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "",
      "Countries": [
        "PO",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context"
      ],
      "Original_Comparator_Variants": [
        ""
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK",
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "adagrasib"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with non–smallcell lung cancer stage IIIB/IV and a KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "chemotherapy"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE",
        "DK",
        "EN",
        "NL",
        "PT"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
        "patients with non–small-cell lung cancer stage IIIB/IV and an KRAS G12C mutation"
      ],
      "Original_Comparator_Variants": [
        "docetaxel"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "DE",
        "EN",
        "PT"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "docetaxel in combination with nintedanib",
        "docetaxel plus nintedanib",
        "docetaxel + nintedanib"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "investigator’s choice chemotherapy (gemcitabine, docetaxel, or pemetrexed)",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy"
      ],
      "Original_Comparator_Variants": [
        "investigator’s choice chemotherapy (gemcitabine 1250mg/m2 days 1 and 8 every 21 days, docetaxel 75 mg/m2 day 1 every 21 days, or pemetrexed 500 mg/m2 day 1 every 21 days)"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "nivolumab"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)"
      ],
      "Original_Comparator_Variants": [
        "pembrolizumab"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "DE",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and except in cases of predominantly squamous histology"
      ],
      "Original_Comparator_Variants": [
        "pemetrexed"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy"
      ],
      "Original_Comparator_Variants": [
        "platinum doublet"
      ]
    },
    {
      "Population": "Adults with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy (including those previously treated with platinum-based chemotherapy and/or immunotherapy)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DE",
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy",
        "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy"
      ],
      "Original_Comparator_Variants": [
        "currently approved (02/22) Sotorasib",
        "sotorasib"
      ]
    }
  ]
}